Molecular Devices Inks Deal with ChanTest for Ion Channel, GPCR Cell Lines | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Devices will distribute ChanTest's portfolio of ion channel and GPCR cell lines under a non-exclusive deal announced today.

As part of the deal, Molecular Devices will also sell ChanTest's cell optimization services to Molecular Devices' customers worldwide using its PatchXpress 7000A, IonWorks Quattro, IonWorks Barracuda, and FLIPR Tetra systems.

Based in Cleveland, ChanTest has more than 145 ion channel and 110 GPCR cell lines

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.